# Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

> **NCT01046487** · PHASE1 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 26 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Imatinib mesylate, Cyclophosphamide (Dosing level 1 )
- **DRUG:** Imatinib mesylate, Cyclophosphamide (Dosing level 2)
- **DRUG:** Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- **PROCEDURE:** Blood sampling

## Key facts

- **NCT ID:** NCT01046487
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-09
- **Primary completion:** 2011-04
- **Final completion:** 2012-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046487, "Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01046487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*